Enveda news
The latest Enveda news, : Anthropic partners with pharma firms to cut document review by 89%.
Enveda is a biotech startup that uses artificial intelligence to discover medicines from plants and microbes. It is a partner in Anthropic’s drug‑development collaborations with six life‑science firms, and it recently secured a $311 million Series E financing round led by Catalio Capital Management.
3 stories mentioning Enveda since 23 September 2026, newest first, each with its sources and discussion. Follow to see new ones on your front page.
Funding and deals $311M reported
- $311Mlate-stage round at a $2.0B valuationSept 2026 · Catalio Capital Management, Iconiq
-
Anthropic partners with pharma firms to cut document review by 89%
Anthropic is expanding its Claude AI model into pharmaceutical research, collaborating with biotech firms to accelerate drug development. The company detailed these efforts in a new blog post, highlighting projects…
1 sourcetech.yahoo.com -
Anthropic details drug development work with six partners and acquires Mithril
Anthropic disclosed deep research partnerships with six life-sciences organizations — BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group — and said it…
3 sources primary source HN 39finance.yahoo.comanthropic.comUnite.AI -
Enveda raises $311 million Series E to advance nature-derived AI drugs
Enveda, a biotech startup that applies artificial intelligence to discover medicines from plants and microbes, announced a $311 million Series E financing round. The round was led by Catalio Capital Management with…
1 sourceTechCrunch AI
Questions about Enveda
What is the latest Enveda news?
As of 1 November 2026: Anthropic partners with pharma firms to cut document review by 89%. Anthropic is expanding its Claude AI model into pharmaceutical research, collaborating with biotech firms to accelerate drug development.
What is Enveda?
Enveda is a biotech startup that uses artificial intelligence to discover medicines from plants and microbes. It is a partner in Anthropic’s drug‑development collaborations with six life‑science firms, and it recently secured a $311 million Series E financing round led by Catalio Capital Management.
How much funding has Enveda raised?
Enveda has $311M in reported deals covered by Digest AI: $311M late-stage round in September 2026.